Results 11 to 20 of about 3,040,782 (318)

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

New England Journal of Medicine, 2015
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma.
R. Motzer, B. Escudier, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, T. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. Gauler, Takeshi Ueda, Y. Tomita, F. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. Simon, Li-an Xu, I. Waxman, Padmanee Sharma   +26 more
semanticscholar   +1 more source

Symptomatic venous thromboembolism associated with peripherally inserted central catheters predicts a worse survival in nasopharyngeal carcinoma: results of a large cohort, propensity score–matched analysis

BMC Cancer, 2018
Background Despite increasing use, symptomatic venous thromboembolism (VTE) associated with peripherally inserted central catheter (PICC) is a common complication in nonmetastatic nasopharyngeal carcinoma (NPC) patients.
Yu-Jing Liang, Lin-Quan Tang, Xue-Song Sun, Yu-Ying Fan, Jin-Jie Yan, Yu-Yun Du, Shan-Shan Guo, Li-Ting Liu, Hao-Jun Xie, Sai-Lan Liu, Qing-Nan Tang, Xiao-Yun Li, Hai-Qiang Mai, Qiu-Yan Chen   +13 more
doaj   +1 more source

Histochemical and immunohistochemical analyses of primary carcinoma of the liver. [PDF]

, 1991
Hematoxylin and eosin (H-E) stained liver sections of 47 autopsy cases of hepatic malignancies were examined. There were 43 cases of hepatocellular carcinoma (subtypes of 30 trabecular, 7 solid, 5 pseudoglandular, and one scirrhous carcinoma), 3 of ...
Hayashi, Keiki, Sacho, Masanori, Setsu, Koujun   +2 more
core   +1 more source

TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer. [PDF]

, 2016
A subgroup of breast cancers has several metabolic compartments. The mechanisms by which metabolic compartmentalization develop in tumors are poorly characterized. TP53 inducible glycolysis and apoptosis regulator (TIGAR) is a bisphosphatase that reduces
Bartrons, Ramon, Birbe, Ruth C., Capparelli, Claudia, Caro, Jaime, Curry, Joseph M., Domingo-Vidal, Marina, Ko, Ying-Hui, Lin, Zhao, Manzano, Anna, Martinez-Outshoorn, Ubaldo E., Navarro-Sabaté, Àurea, Roche, Megan, Seifert, Erin, Tassone, Patrick, Tuluc, Madalina, Whitaker-Menezes, Diana   +15 more
core   +2 more sources

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma

New England Journal of Medicine, 2018
BACKGROUND Nivolumab plus ipilimumab produced objective responses in patients with advanced renal‐cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear‐cell advanced renal ...
R. Motzer, N. Tannir, D. McDermott, O. A. Frontera, B. Melichar, T. Choueiri, E. Plimack, P. Barthélémy, C. Porta, S. George, T. Powles, F. Donskov, V. Neiman, C. Kollmannsberger, P. Salman, H. Gurney, R. Hawkins, A. Ravaud, M. Grimm, S. Bracarda, C. Barrios, Y. Tomita, D. Castellano, B. Rini, Allen C. Chen, S. Mekan, B. McHenry, M. Wind-Rotolo, J. Doan, Padmanee Sharma, H. Hammers, B. Escudier   +31 more
semanticscholar   +1 more source

Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases [PDF]

, 2017
Histopathology is considered the gold standard diagnostic method for canine mammary tumors. In 2011, a new histologic classification for canine mammary tumors was proposed.
Berlato, Davide, Goldschmidt, Michael H., Rasotto, Roberta, Zappulli, Valentina   +3 more
core   +1 more source

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

New England Journal of Medicine, 2019
BACKGROUND The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal‐cell carcinoma.
B. Rini, E. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Soulières, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R. McDermott, J. Bedke, S. Tartas, Yen‐Hwa Chang, S. Tamada, Qiong Shou, R. Perini, Mei Chen, M. Atkins, T. Powles   +26 more
semanticscholar   +1 more source

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Clinical Liver Disease, 2019
and Scope This guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is different from a guideline.
J. Marrero, L. Kulik, C. Sirlin, A. Zhu, R. Finn, M. Abecassis, L. Roberts, J. Heimbach   +7 more
semanticscholar   +1 more source

Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma

Cancer Medicine, 2023
Objectives This study aimed to investigate the incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC).
Lu‐Lu Zhang, Xi Chen, Ying‐Ying Huang, Chi‐Xiong Liang, Meng‐Yun Qiang, Zhuo‐Chen Cai, Ze‐Jiang Zhan, Ying Deng, Jia‐Yu Zhou, Hao‐Yang Huang, Xiang Guo, Xing Lv   +11 more
doaj   +1 more source

Sorafenib in advanced hepatocellular carcinoma.

New England Journal of Medicine, 2008
BACKGROUND No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived ...
G. Spinzi, S. Paggi
semanticscholar   +2 more sources